Krystal biotech, inc. (KRYS)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating Activities
Net loss

-5,341

-5,357

-4,272

-5,348

-4,111

-3,708

-2,755

-2,276

-2,150

-1,393

-5,274

-759

-494

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation

335

250

191

175

132

61

38

24

18

14

5

3

1

Stock-based compensation expense

539

323

278

325

313

302

278

147

65

58

53

44

91

Non-cash interest expense

-

-

-

-

-

-

-

-

-

0

3,190

43

30

(Increase) decrease in
Prepaid expenses and other current assets

-108

426

528

-415

352

367

17

-181

118

275

-76

-49

-73

Prepaid rent

2,400

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of right-of-use asset, net

26

26

68

65

67

-

-

-

-

-

-

-

-

Accounts payable

244

-369

-243

-170

583

-17

108

125

-104

-138

90

165

16

Accrued expenses and other current liabilities

262

-144

263

275

153

163

380

181

-80

-393

762

47

26

Net cash used in operating activities

-6,227

-7,046

-4,243

-4,209

-3,215

-3,518

-1,940

-1,618

-2,369

-

-

-

-

Investing Activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-257

Purchases of property and equipment

1,508

2,279

1,175

1,238

1,707

-

-

-

-

159

12

32

7

Purchases of short-term investments

1,967

1,706

2,218

4,137

512

-

-

-

-

-

-

-

-

Proceeds from maturities of short-term investments

2,170

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of other noncurrent assets

-

-

-

-

263

-

-

-

-

-

-

-

-

Net cash used in investing activities

-1,305

-545

-705

-1,236

-2,482

-

-

-

-

-

-

-

-

Financing Activities
Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-7

Proceeds from the issuance of convertible promissory notes

-

-

-

-

-

-

-

-

-

0

0

999

300

Issuance of common stock, net

243

299

13,167

94,019

40

64,288

9,549

4

6

-

-

-

-

Net cash provided by financing activities

243

299

13,167

94,019

40

64,288

9,549

4

6

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

300

Net decrease in cash and cash equivalents

-7,289

-7,292

8,219

88,574

-5,657

57,003

4,854

-5,415

-2,363

-2,979

49,052

1,559

36

Supplemental Disclosures of Non-Cash Investing and Financing Activities
Unpaid purchases of property and equipment

1,302

-345

713

-62

375

-

-

-

-

-

-

-

-

Unpaid offering costs

22

-

-

35

155

-

-

-

-

-

-

-

-

Unpaid deferred offering costs

-

-

-

-

-

-

-

-

1

-

-

-

-

Initial recognition of right-of-use assets

-

-

-

-

3,394

-

-

-

-

-

-

-

-

Conversion of preferred units to preferred stock

-

-

-

-

-

-

-

-

-

-

-

0

1,306